|
Line of Treatment |
Study Name |
Phase |
Treatment Description |
Patient Population |
|
Neo-adjuvant |
Merrimack
MM-121-02-02-07 |
|
Taxol +/- MM-121
followed by Doxorubicin + Cytoxan
|
HER2-, ER/PR status
known, early stage. |
|
Adjuvant |
Pfizer 3144A2-3004-WW |
|
Neratinib
vs. Placebo after Herceptin |
HER2+, early stage. |
|
Adjuvant |
NSABP B-46-I |
III |
TC vs. TAC vs. TCB (Avastin) |
HER2-, node positive or
high risk node negative. |
|
1st line |
Pfizer 3144A2-3005-WW |
III |
Taxol plus Herceptin vs.
Neratinib |
HER2+, locally recurrent
or metastatic. |
|
2nd line |
Tigris TG-AFP-003 |
II |
AFP464 +/- Faslodex
(X-over okay;
*HER2+ if failed
Herceptin & Tykerb.) |
HER2*-, ER+, progressive
metastatic or recurrent on or w/in 1 year of adjuvant AI. |
|
2nd-3rd
line
|
Enzon EZN-2208-03 |
II |
Peg-SN38 (AT arm only) |
HER2+/- MBC, ER/PR
status known. |
|
Bone Mets |
Novartis CZOL446E2352 |
III |
Zometa every 4 vs. every
12 weeks |
Pre-treated with Zometa. |
